Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: A review of its clinical potential

Therapeutic Advances in Gastroenterology

Volumn 7, Issue 3, 2014, Pages 131-140

  Stedman, Catherine ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

direct acting antivirals; hepatitis C; sofosbuvir

Indexed keywords

DACLATASVIR; RIBAVIRIN; SOFOSBUVIR;

ANEMIA; DEPRESSION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; LIVER TRANSPLANTATION; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS RESISTANCE;

EID: 84899047097     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X13515825     Document Type: Review

References (30)

1. Chen J. Florian J. Carter W. Fleischer R. Hammerstrom T. Jadhav P. et al. (2013) Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144: 1450–1455.
2. Cornpropst M. Denning J. Clemons D. Marbury T. Alcorn H. Smith W. et al. (2012) The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977. J Hepatol 56(Suppl. 2): Abstract 1101.
3. Denning J. Cornpropst M. Clemons D. Fang L. Sale M. Berrey M. et al. (2011) Lack of effect of the nucleoside analog polymerase inhibitor PSI-7977 on methadone PK and PD. Hepatology 54 (4): Abstract 372.
4. Fontaine H. Hezode C. Dorival C. Larrey D. Zoulim F. de Ledinghen V. et al. (2013) SVR 12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS C020-CUPIC). J Hepatol 58(S25–S44): A60.
5. Fontana R. Hughes E. Bifano M. Appelman H. Dimitrova D. Hindes R. et al. (2013) Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 13: 1601–1605.
6. Gane E. Stedman C. Hyland R. Ding X. Svarovskaia E. Subramanian G. et al. (2013 a) Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir plus the NS5A Inhibitor Ledipasvir or the NS5B Non-nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection. Gastroenterology. DOI: 10.1053/j.gastro.2013.11.007.
7. Gane E. Stedman C. Hyland R. Pang P. Ding X. Symonds W. et al. (2013 b) All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study. J Hepatol 58(S1–S24): A14.
8. Gane E. Stedman C. Hyland R. Sorensen R. Symonds W. Hindes R. et al. (2012) Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Hepatology 56(4 Suppl.): A229.
9. Gane E. Stedman C. Hyland R. Ding X. Svarovskaia E. Symonds W. et al. (2013 c) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368: 34–44.
10. Gilead Sciences (2013) Gilead reports interim data from phase 2 LONESTAR study. Available at: http://www.gilead.com/news/press-releases/2013/5/gilead-reports-interim-data-from-phase-2-lonestar-study.
11. Herbst D. Jr Reddy K. (2013) Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs 22: 527–536.
12. Jacobson I. Gordon S. Kowdley K. Yoshida E. Rodriguez-Torres M. Sulkowski M. et al. (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368: 1867–1877.
13. Jacobson I. McHutchison J. Dusheiko G. Di Bisceglie A. Reddy K. Bzowej N. et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405–2416.
14. Kowdley K. Lawitz E. Crespo I. Hassanein T. Davis M. DeMicco M. et al. (2013) Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 381: 2100–2107.
15. Kuntzen T. Timm J. Berical A. Lennon N. Berlin A. Young S. et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769–1778.
16. Lam A. Espiritu C. Bansal S. Micolochick Steuer H. Niu C. Zennou V. et al. (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56: 3359–3368.
17. Lawitz E. Gane E. Lalezari J. Hyland R. Ma J. Symonds W. (2013 a) High concordance of SVR4, SVR 12 and SVR 24 in patients with HCV infection who have received treatment with sofosbuvir. J Hepatol 58(S229–S407): Abstract 848.
18. Lawitz E. Ghalib R. Rodriguez-Torres M. Younossi Z. Corregidor A. Jacobson I. et al. (2013 b) COSMOS Study: SVR 4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders In: Proceedings of the CROI: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA.
19. Lawitz E. Lalezari J. Hassanein T. Kowdley K. Poordad F. Sheikh A. et al. (2013 c) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13: 401–408.
20. Lawitz E. Mangia A. Wyles D. Rodriguez-Torres M. Hassanein T. Gordon S. et al. (2013 d) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368: 1878–1887.
21. Lawitz E. Rodriguez-Torrez M. Cornpropst M. Denning J. Clemons D. McNair L. et al. (2012) The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. J Hepatol 56(Suppl. 2): Abstract 1130.
22. Mathias A. Cornpropst M. Clemons D. Dennings J. Symonds W. (2012) No clinically significant pharmacokinetic drug–drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. Hepatology 56(4 Suppl.): Abstract 1869.
23. Medivir (2013) Medivir announces interim results from cohort 2 of the COSMOS study evaluating Simeprevir and Sofosbuvir in HCV patients with METAVIR scores F3–F4, Press Release. Available at: http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=FEBC5055C8C2C046&year=2013.
24. Murakami E. Tolstykh T. Bao H. Niu C. Steuer H. Bao D. et al. (2010) Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 285: 34337–34347.
25. Poordad F. McCone J. Jr Bacon B. Bruno S. Manns M. Sulkowski M. et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195–1206.
26. Rodriguez-Torres M. Lawitz E. Kowdley K. Nelson D. Dejesus E. McHutchison J. et al. (2013) Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial. J Hepatol 58: 663–668.
27. Sofia M. Bao D. Chang W. Du J. Nagarathnam D. Rachakonda S. et al. (2010) Discovery of a beta-d-2’-deoxy-2’-alpha-fluoro-2’-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 53: 7202–7218.
28. Sulkowski M. Gardiner D. Rodriguez-Torres M. Reddy K. Hassanein T. Jacobson I. et al. (2012) High rate of sustained virological response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotypes 1,2, or 3. Hepatology 56 (6): 1516A.
29. Sulkowski M. Gardiner D. Rodriguez-Torres M. Reddy K. Hassanein T. Jacobson I. et al. (2013) Sustained virological response with daclatasvir, plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol 58(S567–S577): Abstract 1417.
30. Younossi Z. Stepanova M. Mir H. Jacobson I. Gane E. Nader F. et al. (2013) Minimal impact of sofosbuvir + ribavirin on health related quality of life (HRQL) compared to pegylated interferon + ribavirin for chronic hepatitis C: results from FISSION + POSITRON trials. J Hepatol 58(S567–S577): Abstract 1431.